A Long-Term Study of JNT-517 in Participants With Phenylketonuria

Summary

The goal of this Phase 3, open-label study is to evaluate the long-term safety of JNT-517 in pediatric and adult participants with Phenylketonuria (PKU) after completion of either Study JNT517-101 (NCT05781399) or JNT517-201 (NCT06637514) as well as participants who have not participated in a prior JNT-517 study. In this trial, all participants will receive JNT-517 using age- and weight-banded dosing as outlined in the protocol, regardless of any dose received in a previous study.

Timeline

Start

2025-08-11

Primary completion

2027-11-01

Completion

2028-02-01

Drugs

Indications